Evofem Q3 revenue $5.1M (-20% YoY); op loss narrows 81%; debt restructured; generic threat removed

Evofem Biosciences, Inc.

2023-Q3 EPS reported $0.09 vs consensus -$0.06 ▲ beat (+247.1%)

Net product sales $5.1M in Q3 vs $6.4M YoY; selling and marketing expenses cut 75%.
Net income $66M ($15.34 basic) from debt extinguishment gain; operating loss improved to $3.6M from $18.7M.
Fourth Amendment to $25M notes: waived default, removed revenue covenant; repurchase possible for as low as $14M.
Generic drug maker withdrew ANDA; will not seek FDA approval until Evofem Phexxi patents expire (2033).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evofem Biosciences, Inc. reported third quarter ended September 30, 2023 results: revenue $5.1 million in net product sales, net income net income was $66.0 million, EPS $15.34 per basic and $0.10 per diluted share.

Period: third quarter ended September 30, 2023
Revenue: $5.1 million in net product sales
Net income: net income was $66.0 million
EPS: $15.34 per basic and $0.10 per diluted share
Result: reported results

Exact text from the filing

November 14, 2023 —Evofem Biosciences, Inc. (OTCQB: EVFM) today announced financial results for the third quarter and nine months ended September 30, 2023. Highlights include: ● $5.1 million in net product sales of Phexxi ® (lactic acid, citric acid and potassium bitartrate) for the third quarter of 2023 and $13.4 million year-to-date 2023. ○ More than 82% of

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Evofem Biosciences, Inc. reported financial results for three and nine months ended September 30, 2023.

Period: three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Evofem Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.